Gleevec(tm): The New Oral Cancer Treatment That Targets Genetic Defects Present in Tumors

2.50
Hdl Handle:
http://hdl.handle.net/10755/164624
Category:
Abstract
Type:
Presentation
Title:
Gleevec(tm): The New Oral Cancer Treatment That Targets Genetic Defects Present in Tumors
Author(s):
Fedricker, Barber
Author Details:
Fedricker Barber, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
Abstract:
Last year, more than 4500 people in the United States were diagnosed with chronic myelogenous leukemia (CML). CML is a clonal expansion of hematopoietic progenitor cells characterized by myeloid hyperplasia, leukocytosis with basophilia, and splenomegaly. The cytogenetic hallmark of CML, the Philadelphia chromosome, is a reciprocal translocation between the abl proto-oncogene on chromosome nine to the BCR gene on chromosome 22, forming the bcr-abl protein. The bcr-abl protein is an activated tyrosine kinase that transforms normal hematopoietic cells into CML cells. The standard treatment for CML includes interferon, hydroxyurea, and busulfan. The only known cure is allogeneic bone marrow transplant. Recently, the FDA approved the drug Gleevec as treatment of CML, for patients who have failed interferon-alpha therapy. Gleevec is a protein tyrosine kinase inhibitor that inhibits bcr-abl tyrosine kinase and the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-kit. Clinical trials involving patients with CML who received Gleevec in doses ranging from 25 mg to 1000 mg per day, have had exciting results. Specifically, researchers report a 98% hematologic response rate in patients receiving doses of 300 mg or more of Gleevec. Due to the tremendous response of Gleevec in the treatment of CML, several clinical trials have begun to evaluate other cancers that express a growth factor receptor with tyrosine kinase activity. Researchers are investigating Gleevec in the treatment of malignant glioma, meningioma, GI stromal, soft tissue sarcomas, and various leukemias. Nausea, vomiting, periobital edema, interstitial edema, weight gain, neutropenia, thrombocytopenia, and hepato-toxicity are the most common side effects. Nursing implications for those patients receiving Gleevec include nursing assessment; patient education regarding drug administration, drug side effects, and information regarding follow up; insurance coverage; and referral to social services. Gleevec has given patients an alternative therapy with fewer side effects when compared to traditional chemotherapy. Gleevec is a home base oral cancer treatment that will enhance and improve the patient's overall quality of life.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2002
Conference Name:
27th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Washington, D.C., USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleGleevec(tm): The New Oral Cancer Treatment That Targets Genetic Defects Present in Tumorsen_GB
dc.contributor.authorFedricker, Barberen_US
dc.author.detailsFedricker Barber, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USAen_US
dc.identifier.urihttp://hdl.handle.net/10755/164624-
dc.description.abstractLast year, more than 4500 people in the United States were diagnosed with chronic myelogenous leukemia (CML). CML is a clonal expansion of hematopoietic progenitor cells characterized by myeloid hyperplasia, leukocytosis with basophilia, and splenomegaly. The cytogenetic hallmark of CML, the Philadelphia chromosome, is a reciprocal translocation between the abl proto-oncogene on chromosome nine to the BCR gene on chromosome 22, forming the bcr-abl protein. The bcr-abl protein is an activated tyrosine kinase that transforms normal hematopoietic cells into CML cells. The standard treatment for CML includes interferon, hydroxyurea, and busulfan. The only known cure is allogeneic bone marrow transplant. Recently, the FDA approved the drug Gleevec as treatment of CML, for patients who have failed interferon-alpha therapy. Gleevec is a protein tyrosine kinase inhibitor that inhibits bcr-abl tyrosine kinase and the receptor tyrosine kinases for platelet-derived growth factor (PDGF), stem cell factor (SCF), and c-kit. Clinical trials involving patients with CML who received Gleevec in doses ranging from 25 mg to 1000 mg per day, have had exciting results. Specifically, researchers report a 98% hematologic response rate in patients receiving doses of 300 mg or more of Gleevec. Due to the tremendous response of Gleevec in the treatment of CML, several clinical trials have begun to evaluate other cancers that express a growth factor receptor with tyrosine kinase activity. Researchers are investigating Gleevec in the treatment of malignant glioma, meningioma, GI stromal, soft tissue sarcomas, and various leukemias. Nausea, vomiting, periobital edema, interstitial edema, weight gain, neutropenia, thrombocytopenia, and hepato-toxicity are the most common side effects. Nursing implications for those patients receiving Gleevec include nursing assessment; patient education regarding drug administration, drug side effects, and information regarding follow up; insurance coverage; and referral to social services. Gleevec has given patients an alternative therapy with fewer side effects when compared to traditional chemotherapy. Gleevec is a home base oral cancer treatment that will enhance and improve the patient's overall quality of life.en_GB
dc.date.available2011-10-27T12:04:04Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:04:04Z-
dc.conference.date2002en_US
dc.conference.name27th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationWashington, D.C., USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.